The evolving role of high-density lipoprotein in reducing cardiovascular risk

Preventive Cardiology

Volumn 4, Issue 2, 2001, Pages 65-72

  Ballantyne, C M ^a   Rangaraj, G R ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN B100; APOLIPOPROTEIN C; ATORVASTATIN; BEZAFIBRATE; CERIVASTATIN; CLOFIBRATE; COLESTYRAMINE; ESTROGEN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERMEDIATE DENSITY LIPOPROTEIN; LIPID; LIVER TRIACYLGLYCEROL LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; PROGESTERONE; SIMVASTATIN; TRIACYLGLYCEROL; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN;

CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; FLUSHING; GASTROINTESTINAL SYMPTOM; HEPATITIS; HUMAN; LIVER TOXICITY; MYOSITIS; PANCREATITIS; REVIEW; RHABDOMYOLYSIS; RISK FACTOR;

EID: 0035029928     PISSN: 1520037X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1520-037X.2001.00556.x     Document Type: Review

References (65)

1. Range of serum cholesterol values in the population developing coronary artery disease
2. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease
3. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II)
4. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study
5. High-density lipoprotein cholesterol and cardiovascular disease: Four prospective American studies
6. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events
7. Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project
8. The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial
9. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B
10. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy
11. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients
12. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol
13. DAIS trial
14. Baseline HDL-cholesterol and triglycerides as predictors of progression of atherosclerosis in saphenous vein grafts: NHLBI Post-CABG clinical trial
15. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S)
16. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
17. Influence of baseline lipids on effectiveness of pravastatin in the CARE Trial
18. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
19. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
20. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
21. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) Study
22. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
23. Relation of baseline lipids and lipid changes with gemfibrozil to cardiovascular endpoints in the VA-High Density Lipoprotein Intervention Trial (VA-HIT)
24. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: Implications for treatment
25. Molecular mechanisms of reverse cholesterol transport
26. The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation
27. Effects of high-density lipoprotein on acetylcholine-induced coronary vasoreactivity
28. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules
29. Defining specific goals of therapy in treating dyslipidemia in the patient with low high-density lipoprotein cholesterol
30. Cigarette smoking and plasma high-density lipoprotein cholesterol: The Lipid Research Clinics Program Prevalence Study
31. Plasma high-density lipoprotein cholesterol: Association with measurements of body mass
32. Habitual physical activity and high-density lipoprotein cholesterol in men with primary hypercholesterolemia: The Lipid Research Clinics Coronary Primary Prevention Trial
33. Long-term cholesterol-lowering effects of 4 fat-restricted diets in hypercholesterolemic and combined hyperlipidemic men: The Dietary Alternatives Study
34. A low-fat diet supplemented with monounsaturated fat results in less HDL-C lowering than a very-low-fat diet
35. Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man
36. Niacin accelerates intracellular apoB degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells
37. Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells: Implication for reverse cholesterol transport
38. Hepatic toxicity of unmodified and time-release preparations of niacin
39. A new extended-release niacin (Niaspan): Efficacy, tolerability, and safety in hypercholesterolemic patients
40. Efficacy and safety of an extended-release niacin (Niaspan): A long-term study
41. Mechanism of action of fibrates on lipid and lipoprotein metabolism
42. Post-prandial lipemia, fenofibrate and coronary artery disease
43. Fenofibrate for the treatment of type IV and V hyperlipoproteinemias: A double-blind, placebo-controlled multicenter US study
44. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy
45. Oral estrogen replacement therapy in postmenopausal women selectively raises levels and production rates of lipoprotein A-I and lowers hepatic lipase activity without lowering the fractional catabolic rate
46. Estradiol-induced alteration of very-low-density lipoprotein assembly
47. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins
48. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial
49. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
50. The Estrogen Replacement and Atherosclerosis (ERA) study: Study design and baseline characteristics of the cohort
51. Effects of estrogen replacement on the progression of coronary artery atherosclerosis
52. Design of the Women's Health Initiative clinical trial and observational study
53. Effects of simvastatin (40 and 80 mg/day) in patients with mixed hyperlipidemia
54. Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I
55. Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels
56. Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease
57. Atorvastatin increases low-density lipoprotein size and enhances high-density lipoprotein cholesterol concentration in male, but not in female patients with familial hypercholesterolemia
58. Secondary prevention of heart disease amongst patients with lipid abnormalities: Practice and trends in the United States
59. Combination therapy with fluvastatin and niacin in hypercholesterolemia: A preliminary report on safety
60. Combination therapy with low-dose lovastatin and niacin is as effective as higher-dose lovastatin
61. Fluvastatin with and without niacin for hypercholesterolemia
62. Treatment of hyperlipidemia with combined niacin-statin regimens
63. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia
64. Fenofibrate plus simvastatin therapy versus simvastatin plus cholestyramine therapy for familial hypercholesterolaemia